E2 ModeratePreliminaryPEM not requiredObservationalPeer-reviewedMachine draft
Standard · 3 min
Parvovirus B19 infection--persistence and genetic variation.
Kerr, J R, Curran, M D, Moore, J E et al. · Scandinavian journal of infectious diseases · 1995 · DOI
Quick Summary
Researchers followed 53 people who had acute parvovirus B19 infection (a virus that causes rash and joint pain) for several years. They found that 7 people, all women, still had the virus detectable in their blood years later. Of these 7, one person developed chronic fatigue syndrome along with persistent joint pain, suggesting that B19 infection might sometimes persist in the body and potentially trigger long-term symptoms.
Why It Matters
This study provides early evidence that parvovirus B19 can persist in the body long after acute infection and may be associated with chronic symptoms including fatigue and joint pain—conditions core to ME/CFS. Understanding viral persistence mechanisms could inform investigation of infectious triggers in ME/CFS etiology and guide future therapeutic approaches targeting persistent viral reservoirs.
Observed Findings
7 of 53 patients (all women) had detectable serum B19 DNA at follow-up (26–85 months post-infection), versus none in controls (p = 0.016).
Three of the 7 persistently infected patients reported ongoing symptoms: chronic hemolytic anemia (n=1), persistent bilateral knee arthralgia (n=1), and unilateral knee arthralgia with chronic fatigue syndrome (n=1).
Genetic analysis revealed identical SSCP types in 5 of 7 follow-up isolates, indicating genetic stability of persisting virus in most cases.
Two patients showed different SSCP types between acute and follow-up sampling, suggesting either viral evolution or reinfection.
One persistently infected patient carried two distinct B19 virus types at follow-up assessment.
Inferred Conclusions
Parvovirus B19 can persist in serum for extended periods (2–7 years) in a minority of infected individuals, predominantly women.
Viral persistence may be associated with chronic clinical manifestations including arthralgia, hemolytic anemia, and chronic fatigue syndrome.
Most persistent infections show genetic continuity with the acute-phase virus, though some cases exhibit genetic variation suggestive of viral evolution or superinfection.
Remaining Questions
What viral or host factors predispose certain individuals (particularly women) to B19 persistence versus clearance?
What This Study Does Not Prove
This study does not prove that B19 causes ME/CFS; it is a small descriptive study with only one patient meeting both criteria (persistent infection and chronic fatigue syndrome). The study does not establish causation, does not include a representative ME/CFS cohort, and does not characterize whether viral persistence directly drives symptom development or is merely coincidental.
Tags
Symptom:PainFatigue
Biomarker:Blood Biomarker
Phenotype:Infection-Triggered
Method Flag:Weak Case DefinitionSmall SampleExploratory OnlySex-Stratified
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Does B19 viral persistence directly cause chronic symptoms, or is it a bystander finding in patients with pre-existing susceptibility to chronic illness?
What is the prevalence of B19 persistence in well-characterized ME/CFS cohorts, and does B19 seropositivity or persistent infection correlate with disease severity?
What is the mechanism by which B19 persistence might trigger or perpetuate fatigue and arthralgia?